Eli Lilly has recently shared additional findings regarding its obesity medication, Foundayo (orforglipron), in response to the U.S. Food and Drug Administration’s (FDA) safety concerns regarding the therapy.
FDA’s Safety Concerns
In a new drug application (NDA) approval letter, the FDA expressed the need for clinical studies to assess Foundayo’s safety profile within the general population. Special attention is being directed toward its effects on younger pediatric patients and pregnant women.
The FDA’s request stems from early safety signals linked to Foundayo, which cannot be addressed through nonclinical or observational studies. These signals include potential risks of major adverse cardiovascular events (MACE), drug-induced liver injury (DILI), and a specific type of thyroid cancer.
Promising Phase III Trial Results
In light of these concerns, Lilly has released results from the Phase III ACHIEVE-4 trial (NCT05803421). This study indicated that patients using Foundayo showed a non-inferior risk for MACE—such as heart attacks, strokes, cardiovascular deaths, or sudden chest pain—when compared to those on insulin glargine. Furthermore, no safety signals related to liver toxicity were identified in this trial.
Armed with these results, Lilly is preparing to seek approval for Foundayo in treating type 2 diabetes, with plans to submit an NDA to the FDA by the end of the second quarter of 2026.
Additional Safety Evaluations Required
Despite the encouraging findings from the ACHIEVE-4 trial, the FDA is demanding further evidence of Foundayo’s safety in pediatric patients aged six to twelve, as well as in pregnant individuals. This is due to the agency’s findings of “unexpected serious” risks linked to long-term use of the medication. The required studies in pregnant populations will evaluate outcomes for both mothers and fetuses, along with infants exposed to Foundayo during pregnancy and breastfeeding.
Moreover, Lilly is tasked with gathering more data on the drug’s potential impact on the incidence of medullary thyroid carcinoma over a 15-year period.
Regulatory Background and Industry Reception
Lilly originally gained approval for Foundayo through the Commissioner’s National Priority Voucher (CNPV) scheme. When this initiative was introduced, it led to some uncertainty within the industry, as many felt the requirements for obtaining a voucher were not clearly defined.
Analyst Perspectives on ACHIEVE-4 Data
Prior to the release of the ACHIEVE-4 results, there were apprehensions among industry experts about how the FDA’s additional requirements might influence Foundayo’s long-term success.
However, after the data was published, Shehroz Mahmood, a senior obesity analyst at GlobalData, remarked that the evidence of cardiovascular non-inferiority and the absence of liver toxicity concerns effectively mitigated these worries. He expressed confidence in Lilly’s ability to manage the post-marketing surveillance effectively.
Mahmood noted that the FDA’s requests are typical post-marketing commitments for drugs approved through expedited review processes. He emphasized that these requirements should not significantly disrupt Foundayo’s commercial acceptance or its competitive stance against Novo Nordisk’s oral Wegovy (semaglutide).
Competitive Landscape and Market Positioning
Mahmood further elaborated that the liver monitoring requirements post-approval are standard and should not hinder Foundayo’s market entry. He compared this situation to that of oral semaglutide, which benefitted from years of data from Rybelsus before Wegovy’s approval.
With Lilly proactively sharing data that shows no safety signals throughout the development process, Mahmood believes Foundayo is well-positioned to leverage its advantages in convenience and supply scalability, rather than being hampered by safety perceptions.
Conclusion
Eli Lilly’s ongoing commitment to transparency and proactive data sharing may prove beneficial as it navigates the regulatory landscape for Foundayo. The promising results from the Phase III trial bolster the drug’s potential, while the FDA’s requirements for post-marketing studies will ensure continued scrutiny of safety. As the company prepares for future submissions, it remains to be seen how these developments will shape the competitive landscape in obesity treatment.
- Key Takeaways:
- Lilly presented new data for Foundayo following FDA safety concerns.
- The ACHIEVE-4 trial showed favorable cardiovascular risk profiles.
- The FDA requires additional studies on pediatric and pregnant populations.
- Analysts remain optimistic about Foundayo’s market potential despite regulatory hurdles.
- The drug competes directly with Novo Nordisk’s Wegovy amidst evolving safety evaluations.
Read more → www.yahoo.com